FDA guidance on antihyperglyacemic therapies for type 2 diabetes: One decade later
Year: 2019
Type: article
Source: Diabetes Obesity and Metabolism
DOI: 10.1111/dom.13645
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Keywords: type 2 diabetes, antihyperglycemic therapy, cardiovascular safety, cardiovascular outcome trials, DPP-4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors, major adverse cardiovascular events, empagliflozin, liraglutide, canagliflozin, atherosclerotic cardiovascular disease, drug development costs, trial design
Open Access status: closed
Funder: Boehringer Ingelheim
OpenAlex ID: W2911825173
